Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Cormedix Inc
CRMD
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.10
0.31
3.98%
Últ. Act.: Oct 22, 6:02 PM
$8.09
0.30
3.85%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Cormedix Financials
Cormedix (CRMD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.
Vandana Singh
PRO
Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate
Benzinga Newsdesk
PRO
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $334.089M Est
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $334.089 million estimate.
Benzinga Newsdesk
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix raises 2026 guidance after Q1 revenue surges on strong DefenCath demand and higher profitability.
Vandana Singh
PRO
Cormedix Raises FY2026 Sales Guidance from $300.000M-$320.000M to $325.000M-$345.000M vs $308.224M Est
Cormedix (NASDAQ:CRMD) raises FY2026 sales outlook from $300.000 million-$320.000 million to $325.000 million-$345.000 million vs $308.224 million estimate.
Benzinga Newsdesk
PRO
Cormedix Q1 Adj. EPS $0.43 Beats $0.36 Estimate, Sales $127.427M Beat $105.017M Estimate
Cormedix (NASDAQ:CRMD) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.36 by 16.22 percent. This is a 43.33 percent increase over earnings of $0.30 per share from the same
Benzinga Newsdesk
